RMTC Forms Task Force to Examine Glaucine

The Racing Medication and Testing Consortium has formed a task force to review information on glaucine and address the issue of recent positives for the substance.

Earlier this year several RMTC-accredited laboratories finalized positive tests for the substance.

Glaucine is legally available in several eastern European and western Asian countries. The purported therapeutic effects include bronchodilation and anti-inflammation. In addition, it is reported to be used as a drug of abuse in humans for its psychedelic properties. 

Although it has the potential to enhance performance, there is also the possibility of environmental contamination to consider—depending on concentrations—as glaucine is found in the tulip poplar tree. Wood from the tree is sometimes found in equine bedding made of wood shavings or sawdust. The tree is indigenous to the eastern United States.

Members of the RMTC's Scientific Advisory Committee, including several who have already begun researching the issue, have agreed to participate in this effort. Task force members are:

•    Dr. Adam Chambers, Ontario Racing Commission 

•    Dr. Scott Stanley, University of California, Davis Maddy Laboratory

•    Dr. Lynn Hovda, Minnesota Racing Commission

•    Dr. Mary Robinson, Pennsylvania Equine Toxicology Research Laboratory

•    Dr. Scott Palmer, New York State Gaming Commission

•    Dr. Anthony Fontana, Truesdail Laboratories

•    Al Kind, Texas A & M Veterinary Diagnostic Laboratory

The task force will identify existing information, determine what research, if any, needs to be conducted, and develop a plan to address the use of glaucine as a performance enhancer, as well as address potential sources of environmental contamination for the compound. 

Since glaucine is not currently listed in the ARCI's Uniform Classification Guidelines for Foreign Substances and Recommended Penalties, a recommendation for inclusion in the ARCI guidelines will be considered as well.